In CML patients treated with imatinib, NGS has enabled identification of novel BCR-ABL1 fusions gene comprising BCR intron 14 and ABL1 intron 2 breakpoints, giving partial deletion of SH3 domain [29]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.